Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Revenue of Design Therapeutics, Inc. (DSGN)
Revenue in 2023 (TTM): $
According to Design Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Design Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-537,000 | $-78,190,000 | $-66,862,000 | $-66,862,000 |
| 2022 | $ | $-466,000 | $-67,593,000 | $-63,308,000 | $-58,617,000 |
| 2021 | $ | $-129,000 | $-35,702,000 | $-35,533,000 | $-35,533,000 |
| 2020 | $226 | $-4,774 | $-8,325,000 | $-8,280,000 | $-8,280,000 |
| 2019 | $834 | $-820 | $-1,908,000 | $-2,047,000 | $-2,047,000 |